Hacettepe University
Ankara, Turkey (Türkiye)
Location contact
Alper Kemal Gurbuz, MSc
CONTACT
Aynur Demirel, PT, PhD
CONTACT
Hidaye Yamikan, MSc
CONTACT
Hidaye Yamikan, PT,MSc
CONTACT
Ugur Canpolat, MD, Prof.
CONTACT
İrem Suzen, MSc
CONTACT
NCT Number: NCT06681714
The aim of this study is to evaluate The Validity and Reliability of the Turkish Version of the Heart Failure Somatic Perception Scale in patients with heart failure.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Ankara, Turkey (Türkiye)
Alper Kemal Gurbuz, MSc
CONTACT
Aynur Demirel, PT, PhD
CONTACT
Hidaye Yamikan, MSc
CONTACT
Hidaye Yamikan, PT,MSc
CONTACT
Ugur Canpolat, MD, Prof.
CONTACT
İrem Suzen, MSc
CONTACT
Heart failure is a global health issue that serves as the endpoint for many cardiovascular conditions, particularly coronary heart disease and hypertension. Common symptoms of heart failure include fatigue, dyspnea, edema, cough, lack of energy, orthopnea, paroxysmal nocturnal dyspnea, palpitations, and dizziness. These symptoms significantly affect the health-related quality of life of individuals with heart failure, especially in the palliative phase of the disease. Additionally, heart failure patients often experience physical limitations, reduced quality of life, and an increased rate of hospital admissions due to symptoms such as breathlessness and fatigue. The Heart Failure Somatic Perception Scale assesses the presence and severity of 18 common physical signs and symptoms of heart failure (e.g. chest pain), as well as dyspnea and its impact on daily activities through six items. Robust and rigorous measures are needed to assess the complexity of heart failure symptoms, and evidence suggests that evaluating a broad range of heart failure symptoms can be beneficial in guiding rehabilitation approaches, clinical decision-making, and survival prediction.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
A diagnosis of heart failure. Use of optimal pharmacological treatment according to current guidelines for at least 3 months.
Functional capacity classified as New York Heart Association (NYHA) Class I-IV (ambulatory).
Age 18 or older. Ability to cooperate with measurements.
Exclusion criteria
Known cognitive impairment. Having undergone acute coronary syndrome, percutaneous coronary intervention, or heart surgery within the past three months.
Time frame: 1 day
The Heart Failure Somatic Perception Scale comprises 18 items that assess how much the main signs and symptoms of heart failure have distressed the individual over the past week.
Each item is rated on a five-point Likert scale, ranging from 0, indicating "did not experience this symptom," to 5, indicating "severe distress." The total score is obtained by summing the scores of all items, yielding a range from 0 to 90.
A higher score indicates a greater impact of heart failure symptoms on the patient's life.
Turkish version of The Heart Failure Somatic Perception Scale will be applied.
Time frame: 1 day
The Heart Failure Symptom Status Scale is designed to assess the presence, frequency, severity, and impact of the seven most common symptoms in patients with heart failure.
Patients evaluate the presence, frequency, and severity of symptoms such as dyspnea, orthopnea, fatigue, chest pain, edema, sleep disturbances, dizziness, or lightheadedness using a four-point Likert scale.
The total score attainable on this scale ranges from 0 to 84.
Time frame: 1 day
The Mini-Mental test was developed to assess cognitive impairment in adults. It is structured under five main categories: orientation, registration memory, attention and calculation, recall, and language. The test is scored on a total of 30 points. Individuals scoring 17 or below are classified as having severe dementia, those scoring between 18 and 23 are classified with mild dementia, and individuals scoring between 24 and 30 are considered not to have dementia.
Time frame: 1 day
The MacNew Heart Disease-Specific Quality of Life Questionnaire is an internationally recognized tool for measuring health-related quality of life in patients with Coronary Artery Disease (CAD).
The questionnaire is designed to assess how physical, emotional, and social functions, as well as daily activities, are affected by CAD. The questionnaire consists of three subscales: physical limitation, emotional function, and social function, with a total of 27 items. Subscale scores are calculated by averaging the responses to the relevant items. For each subscale and for the total score, the lowest possible score is 1 and the highest is 7, with higher scores indicating better quality of life.
Time frame: 1 day
It is a mortality scoring system that includes 19 comorbidity diagnostic groups. This index is frequently used as an assessment tool for evaluating comorbidities. A score of "1 point" is assigned for the presence of myocardial infarction, congestive heart failure, peripheral vascular diseases, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver disease, and diabetes. A score of "2 points" is given for conditions such as hemiplegia, moderate/severe renal disease, diabetes with end-organ damage, tumors, leukemia, and malignant lymphoma. A score of "3 points" is assigned for moderate/severe liver disease, and "6 points" is given for the presence of metastatic solid tumors and AIDS. The total score is calculated by summing the individual scores, with higher scores indicating more serious conditions and a worse prognosis.
Time frame: 1 day
The Minnesota Living with Heart Failure Questionnaire consists of 21 items that examine the physical and emotional dimensions of heart failure. Items 2, 3, 4, 5, 6, 7, 12, and 13 assess the physical dimension, while items 17, 18, 19, 20, and 21 assess the emotional dimension. Each item is scored on a scale from 0 to 5, with a maximum possible score of 105. Higher scores indicate poorer quality of life.
Time frame: 1 day
The Fatigue Severity Scale is a questionnaire designed to measure the severity of fatigue over the past week. It consists of 9 items, each rated on a scale from 0 to 7. The total score is obtained by summing the responses to all items and dividing the sum by 9. A score of 4 or higher typically indicates severe fatigue.
Time frame: 1 day
The Leicester Cough Questionnaire is a health-related quality of life tool specifically designed for chronic cough. It is a self-administered, easy-to-use form that evaluates the impact of chronic cough on physical, psychological, and social aspects of life. The questionnaire consists of 19 items across these three domains, and it uses a 7-point Likert scale for responses.
Higher scores on the LCQ indicate that the individual is less affected by the cough, reflecting better overall health. The total score is the sum of the scores from the physical, psychological, and social domains.
Contact information is provided by the study sponsor or research team.
Aynur Demirel, PT, PhD
CONTACT
Hidaye Yamikan, PT,MSc
CONTACT
Hacettepe University
Other
Kalp Yetersizliği Somatik Algı Ölçeğinin Türkçe Geçerlik Ve Güvenirlik Çalışması
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07740044
Arrhythmias, Cardiac, Arterial Occlusive Diseases
Taizhou, Jiangsu, China
View Trial DetailsNCT07737964
Cardiovascular Diseases, Heart Diseases
Amiens, France
View Trial DetailsNCT07731048
Cardiovascular Diseases, Heart Diseases
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT05996328
Cardiovascular Diseases, Heart Diseases
Ann Arbor, Michigan, United States
View Trial Details